$123 Million is the total value of Stonepine Capital Management, LLC's 17 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 60.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TBRA | Buy | Tobira Therapeutics, Inc. | $29,158,000 | +264.1% | 733,718 | +15.1% | 23.78% | +189.6% |
| VIVE | New | Viveve Medical, Inc | $18,770,000 | – | 2,599,711 | +100.0% | 15.31% | – |
| Buy | Aegerion Pharmaceuticals, Inc.note | $15,957,000 | +61.8% | 24,200,000 | +39.9% | 13.01% | +28.7% | |
| ALR | Buy | Alere Inc. | $12,395,000 | +296.5% | 286,651 | +282.2% | 10.11% | +215.4% |
| QLTI | Buy | QLT Inc. | $11,904,000 | +121.8% | 5,778,496 | +52.9% | 9.71% | +76.4% |
| REPH | Buy | Recro Pharma, Inc. | $10,348,000 | +203.6% | 1,170,600 | +173.1% | 8.44% | +141.5% |
| CRME | New | Cardiome Pharma Corp | $6,006,000 | – | 1,918,722 | +100.0% | 4.90% | – |
| CUTR | Sell | Cutera, Inc. | $4,768,000 | -2.9% | 400,000 | -8.7% | 3.89% | -22.8% |
| VCEL | Sell | Vericel Corp | $2,865,000 | -43.4% | 1,023,048 | -54.5% | 2.34% | -55.0% |
| ALIM | New | Alimera Sciences, Inc | $2,842,000 | – | 1,907,190 | +100.0% | 2.32% | – |
| DRRX | Buy | Durect Corporation | $2,288,000 | +2234.7% | 1,646,170 | +1953.6% | 1.87% | +1766.0% |
| CPIX | Buy | Cumberland Pharmaceuticals, Inc. | $1,622,000 | +179.7% | 323,747 | +151.4% | 1.32% | +122.4% |
| Pernix Therapeutics Holdingsnote | $1,564,000 | +13.3% | 6,000,000 | 0.0% | 1.28% | -9.9% | ||
| JNP | New | Juniper Pharmaceuticals, Inc. | $966,000 | – | 173,967 | +100.0% | 0.79% | – |
| AVIR | Buy | Aviragen Therapeutics, Inc. | $667,000 | +61.9% | 347,440 | +18.1% | 0.54% | +28.9% |
| DSCI | Sell | Derma Sciences, Inc. | $458,000 | -59.0% | 98,064 | -65.4% | 0.37% | -67.4% |
| PCRX | Sell | Pacira Pharmaceuticals, Inc. | $51,000 | -97.1% | 1,500 | -97.1% | 0.04% | -97.7% |
| VCYT | Exit | Veracyte, Inc. | $0 | – | -186,926 | -100.0% | -0.96% | – |
| Exit | Enanta Pharmaceuticals, Inc. | $0 | – | -52,616 | -100.0% | -1.19% | – | |
| BSTC | Exit | BioSpecifics Technologies Corp. | $0 | – | -30,000 | -100.0% | -1.23% | – |
| FLML | Exit | Flamel Technologies SA | $0 | – | -128,005 | -100.0% | -1.41% | – |
| SCMP | Exit | Sucampo Pharmaceuticals, Inc. | $0 | – | -213,860 | -100.0% | -2.40% | – |
| SGNT | Exit | SAGENT PHARMACEUTICALS INC | $0 | – | -356,307 | -100.0% | -5.47% | – |
| PTIE | Exit | PAIN THERAPEUTICS INC | $0 | – | -2,837,878 | -100.0% | -6.37% | – |
| VNDA | Exit | VANDA PHARMACEUTICALS INC | $0 | – | -811,563 | -100.0% | -9.31% | – |
| Exit | Viveve Medical, Inc | $0 | – | -2,599,711 | -100.0% | -10.93% | – | |
| SCLN | Exit | SCICLONE PHARMACEUTICALS INC | $0 | – | -1,082,532 | -100.0% | -14.50% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.